Cargando…

Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use

Undifferentiated pleomorphic sarcoma (UPS), a subtype of soft tissue sarcoma (STS), is an uncommon malignancy associated with a poor prognosis. As with other forms of sarcoma, surgical resection remains the only form of treatment with curative potential. The role of perioperative systemic therapy ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Won Jin, Moon, Jin Hyun, Pham, Bryan, Joung, Bowon, Denham, Laura, Brothers, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327587/
https://www.ncbi.nlm.nih.gov/pubmed/37427109
http://dx.doi.org/10.3389/fonc.2023.1198292
_version_ 1785069657943703552
author Jeon, Won Jin
Moon, Jin Hyun
Pham, Bryan
Joung, Bowon
Denham, Laura
Brothers, Joel
author_facet Jeon, Won Jin
Moon, Jin Hyun
Pham, Bryan
Joung, Bowon
Denham, Laura
Brothers, Joel
author_sort Jeon, Won Jin
collection PubMed
description Undifferentiated pleomorphic sarcoma (UPS), a subtype of soft tissue sarcoma (STS), is an uncommon malignancy associated with a poor prognosis. As with other forms of sarcoma, surgical resection remains the only form of treatment with curative potential. The role of perioperative systemic therapy has not been definitively elucidated. Due to high recurrence rates and metastatic potential, management of UPS can pose a difficult task for clinicians. In cases of unresectable UPS due to anatomic limitations and in patients with comorbidities and poor performance status (PS), management options are limited. We describe a patient with UPS involving the chest wall with poor PS who achieved complete response (CR) following neoadjuvant chemotherapy and radiation in the setting of prior immune-checkpoint inhibitor (ICI) therapy.
format Online
Article
Text
id pubmed-10327587
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103275872023-07-08 Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use Jeon, Won Jin Moon, Jin Hyun Pham, Bryan Joung, Bowon Denham, Laura Brothers, Joel Front Oncol Oncology Undifferentiated pleomorphic sarcoma (UPS), a subtype of soft tissue sarcoma (STS), is an uncommon malignancy associated with a poor prognosis. As with other forms of sarcoma, surgical resection remains the only form of treatment with curative potential. The role of perioperative systemic therapy has not been definitively elucidated. Due to high recurrence rates and metastatic potential, management of UPS can pose a difficult task for clinicians. In cases of unresectable UPS due to anatomic limitations and in patients with comorbidities and poor performance status (PS), management options are limited. We describe a patient with UPS involving the chest wall with poor PS who achieved complete response (CR) following neoadjuvant chemotherapy and radiation in the setting of prior immune-checkpoint inhibitor (ICI) therapy. Frontiers Media S.A. 2023-06-23 /pmc/articles/PMC10327587/ /pubmed/37427109 http://dx.doi.org/10.3389/fonc.2023.1198292 Text en Copyright © 2023 Jeon, Moon, Pham, Joung, Denham and Brothers https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Jeon, Won Jin
Moon, Jin Hyun
Pham, Bryan
Joung, Bowon
Denham, Laura
Brothers, Joel
Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
title Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
title_full Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
title_fullStr Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
title_full_unstemmed Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
title_short Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
title_sort case report: an exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327587/
https://www.ncbi.nlm.nih.gov/pubmed/37427109
http://dx.doi.org/10.3389/fonc.2023.1198292
work_keys_str_mv AT jeonwonjin casereportanexceptionalresponsetoneoadjuvantradiotherapyandchemotherapyinundifferentiatedpleomorphicsarcomafollowingcheckpointinhibitoruse
AT moonjinhyun casereportanexceptionalresponsetoneoadjuvantradiotherapyandchemotherapyinundifferentiatedpleomorphicsarcomafollowingcheckpointinhibitoruse
AT phambryan casereportanexceptionalresponsetoneoadjuvantradiotherapyandchemotherapyinundifferentiatedpleomorphicsarcomafollowingcheckpointinhibitoruse
AT joungbowon casereportanexceptionalresponsetoneoadjuvantradiotherapyandchemotherapyinundifferentiatedpleomorphicsarcomafollowingcheckpointinhibitoruse
AT denhamlaura casereportanexceptionalresponsetoneoadjuvantradiotherapyandchemotherapyinundifferentiatedpleomorphicsarcomafollowingcheckpointinhibitoruse
AT brothersjoel casereportanexceptionalresponsetoneoadjuvantradiotherapyandchemotherapyinundifferentiatedpleomorphicsarcomafollowingcheckpointinhibitoruse